Allergic asthma patients with sensitization to house dust mites (D. pteronyssinus) allergen Respiratory
Conditions
Interventions
- Eosinophils isolation. Eosinophils from study subjects peripheral blood will be isolated by combined centrifugation at the high-density gradient and magnetic separation with commercial eosinophil i
- Eosinophils subtyping. Whole peripheral blood eosinophils will be separated to eosinophil subtypes – rEOS- and iEOS-like blood eosinophils with human antibodies against CD62L, conjugated with magne
- mRNA isolation. Total mRNA from eosinophils will be extracted by using commercial mRNA isolation kits with special columns, according to manufacturers' instruction or Trizol reagent. The current pro
- RNA sequencing. By small RNA the NGS with the designed appropriate libraries will be used to found a miRNA and piRNA (in one analysis) in eosinophils subtypes (Qiagen, Venlo, Netherlands). Moreover,
- Gene expression. The validation process and ncRNAs levels in blood plasma and exosomes wi
Sponsors
Lithuanian University of Health Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Men and women between the ages of 18-70 years 2. Allergic asthma and sensitization to house dust mites (D. pteronyssinus) allergen, approved with 2.1. Medical history and symptoms more than one year 2.2. Skin prick test positive for D. pteronyssinus (positive wheals are those exceeding 3 mm in diameter greater than the negative control) 2.3. Positive bronchial challenge with methacholine or documented reversible bronchial obstruction 3. Premenopausal women if pregnancy test is negative 4. Healthy subjects without allergic and other chronic respiratory diseases (control group) 5. Participants who gave his/her informed written consent
Exclusion criteria
Exclusion criteria: 1. Asthma exacerbation 1 month prior to study 2. Clinically significant permanent allergy symptoms such as cat or dog dander induced allergy 3. Contraindications to perform an allergy skin test and or bronchial provocation test 3.1. Active airway infection 1 month prior to the study 3.2. Used medicaments 3.2.1. Inhaled glucocorticoids intake 1 month prior to the study 3.2.2. Antihistamines intake 7 days prior to the study 3.3. Short acting beta 2 agonists 12 hours prior to the study 3.4. Long acting beta 2 agonists 2 days prior to the study 3.5. Leukotriene receptor antagonists 14 days prior to the study 4. Contraindications for epinephrine 5. Other significant mental and or internal diseases and conditions which could be exclusion criteria in the opinion of the researcher 6. Alcohol or narcotic abuse 7. Pregnancy 8. Breast feeding
Countries
Lithuania
Contacts
Public ContactKestutis Malakauskas
Outcome results
None listed